ArticlePharmaceutics2022
Phage Therapy against
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Novel Silviavirus phages with broad-host-range activity against methicillin resistant Staphylococcus aureus from seafood: comprehending the phenotypic and genotypic variability.Folia microbiologica · 2026Article
- Lactoferrin Displays Stimulating and Protective Effects on Newly Isolated Phage vB_Sau-E: A New Perspective for Treatment of Staphylococcal Skin Infections.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Genomic characterization and comparative analysis of a new Tequatrovirus phage infecting Escherichia coli ST131.BMC research notes · 2026Article
- Review
- Bacteriophages targetingFrontiers in microbiology · 2026Review
- Detachable dissolving microneedles loaded withFrontiers in microbiology · 2026Article
- Staphylococcal phages as agents of evolution and innovation: From gene flow to next-generation therapeutics.Genetics and molecular biology · 2026Article
- Isolation and characterization of lytic bacteriophages against Staphylococcus aureus.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- [Potential of bacteriophage therapy in Germany: evidence and clinical relevance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Review
- In Vitro Activity of Bacteriophages Against Ocular Methicillin-resistant S. aureus Isolates Collected in the US.Ophthalmology and therapy · 2025Article
- Characterization of Newly IsolatedMicroorganisms · 2025Article
- Antibiotic Resistance ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Prevalence and genomic insights into type III-A CRISPR-Cas system acquisition in globalFrontiers in cellular and infection microbiology · 2025Article
- Real-time monitoring by interferometric light microscopy of phage suspensions for personalised phage therapy.Scientific reports · 2024Article
- Potential of training of anti-mSystems · 2024Article
- Isolation and characterisation of a novel Silviavirus bacteriophage promising antimicrobial agent against methicillin-resistant Staphylococcus aureus infections.Scientific reports · 2024Article
- Genetically engineered bacteriophages as novel nanomaterials: applications beyond antimicrobial agents.Frontiers in bioengineering and biotechnology · 2024Review
- Phage Therapy as an Alternative Treatment Modality for ResistantAntibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.